Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 44, Issue 11 1249-1258, Copyright © 1995 by American Diabetes Association

ARTICLES

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group


The objective of the U.K. Prospective Diabetes Study is to determine whether improved blood glucose control in type II diabetes will prevent the complications of diabetes and whether any specific therapy is advantageous or disadvantageous. The study will report in 1998, when the median duration from randomization will be 11 years. This report is on the efficacy of therapy over 6 years of follow-up and the overall incidence of diabetic complications. Subjects comprised 4,209 newly diagnosed type II diabetic patients who after 3 months' diet were asymptomatic and had fasting plasma glucose (FPG) 6.0-15.0 mmol/l. The study consists of a randomized controlled trial with two main comparisons: 1) 3,867 patients with 1,138 allocated to conventional therapy, primarily with diet, and 2,729 allocated to intensive therapy with additional sulfonylurea or insulin, which increase insulin supply, aiming for FPG < 6 mmol/l; and 2) 753 obese patients with 411 allocated to conventional therapy and 342 allocated to intensive therapy with metformin, which enhances insulin sensitivity. In the first comparison, in 2,287 subjects studied for 6 years, intensive therapy with sulfonylurea and insulin similarly improved glucose control compared with conventional therapy, with median FPG at 1 year of 6.8 and 8.2 mmol/l, respectively (P < 0.0001). and median HbA1c of 6.1 and 6.8%, respectively (P < 0.0001). During the next 5 years, the FPG increased progressively on all therapies (P < 0.0001) with medians at 6 years in the conventional and intensive groups, FPG 9.5 and 7.8 mmol/l, and HbA1c 8.0 and 7.1%, respectively. The glycemic deterioration was associated with progressive loss of beta-cell function. In the second comparison, in 548 obese subjects studied for 6 years, metformin improved glucose control similarly to intensive therapy with sulfonylurea or insulin. Metformin did not increase body weight or increase the incidence of hypoglycemia to the same extent as therapy with sulfonylurea or insulin. A high incidence of clinical complications occurred by 6-year follow-up. Of all subjects, 18.0% had suffered one or more diabetes-related clinical endpoints, with 12.1% having a macrovascular and 5.7% a microvascular endpoint. Sulfonylurea, metformin, and insulin therapies were similarly effective in improving glucose control compared with a policy of diet therapy. The study is examining whether the continued improved glucose control, obtained by intensive therapy compared with conventional therapy (median over 6 years HbA1c 6.6% compared with 7.4%), will be clinically advantageous in maintaining health.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
C. P. Tan, Y. Feng, Y.-P. Zhou, G. J. Eiermann, A. Petrov, C. Zhou, S. Lin, G. Salituro, P. Meinke, R. Mosley, et al.
Selective Small-Molecule Agonists of G Protein-Coupled Receptor 40 Promote Glucose-Dependent Insulin Secretion and Reduce Blood Glucose in Mice
Diabetes, August 1, 2008; 57(8): 2211 - 2219.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Festa, K. Williams, A. J.G. Hanley, and S. M. Haffner
{beta}-Cell Dysfunction in Subjects With Impaired Glucose Tolerance and Early Type 2 Diabetes: Comparison of Surrogate Markers With First-Phase Insulin Secretion From an Intravenous Glucose Tolerance Test
Diabetes, June 1, 2008; 57(6): 1638 - 1644.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
J. B. Dixon, P. E. O'Brien, J. Playfair, L. Chapman, L. M. Schachter, S. Skinner, J. Proietto, M. Bailey, and M. Anderson
Adjustable Gastric Banding and Conventional Therapy for Type 2 Diabetes: A Randomized Controlled Trial
JAMA, January 23, 2008; 299(3): 316 - 323.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. N. Davis, D. Johns, D. Maggs, H. Xu, J. H. Northrup, and R. G. Brodows
Exploring the Substitution of Exenatide for Insulin in Patients With Type 2 Diabetes Treated With Insulin in Combination With Oral Antidiabetes Agents
Diabetes Care, November 1, 2007; 30(11): 2767 - 2772.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. Riddle, J. Frias, B. Zhang, H. Maier, C. Brown, K. Lutz, and O. Kolterman
Pramlintide Improved Glycemic Control and Reduced Weight in Patients With Type 2 Diabetes Using Basal Insulin
Diabetes Care, November 1, 2007; 30(11): 2794 - 2799.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
S. D West, D. J Nicoll, T. M Wallace, D. R Matthews, and J. R Stradling
Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes
Thorax, November 1, 2007; 62(11): 969 - 974.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. R. Holman, K. I. Thorne, A. J. Farmer, M. J. Davies, J. F. Keenan, S. Paul, J. C. Levy, and the 4-T Study Group
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
N. Engl. J. Med., October 25, 2007; 357(17): 1716 - 1730.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
E. J. Boyko and C. C. Jensen
Do We Know What Homeostasis Model Assessment Measures?: If not, does it matter?
Diabetes Care, October 1, 2007; 30(10): 2725 - 2728.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
Z. T. Bloomgarden
Exploring Treatment Strategies for Type 2 Diabetes
Diabetes Care, October 1, 2007; 30(10): 2737 - 2745.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
D. Hockaday, M. Sayyad, and C. Yajnik
Counterpoint: Appreciating Homeostasis Model Assessment: More useful earlier rather than later
Diabetes Care, September 1, 2007; 30(9): 2414 - 2418.
[Full Text] [PDF]

Home page
 JAOA: Journal of the American Osteopathic AssociationHome page
C. W. Spellman
Insulin Therapy for Maximal Glycemic Control in Type 2 Diabetes Mellitus
J Am Osteopath Assoc, July 1, 2007; 107(7): 260 - 269.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
L. Blonde
Easing the Transition to Insulin Therapy in People With Type 2 Diabetes
The Diabetes Educator, July 1, 2007; 33(Supplement_7): 232S - 240S.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
P. Hollander, D. Yu, and H. S. Chou
Low-Dose Rosiglitazone in Patients With Insulin-Requiring Type 2 Diabetes
Arch Intern Med, June 25, 2007; 167(12): 1284 - 1290.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
C.-Y. Lin, T. Gurlo, R. Kayed, A. E. Butler, L. Haataja, C. G. Glabe, and P. C. Butler
Toxic Human Islet Amyloid Polypeptide (h-IAPP) Oligomers Are Intracellular, and Vaccination to Induce Anti-Toxic Oligomer Antibodies Does Not Prevent h-IAPP-Induced {beta}-Cell Apoptosis in h-IAPP Transgenic Mice
Diabetes, May 1, 2007; 56(5): 1324 - 1332.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
C. M. Larsen, M. Faulenbach, A. Vaag, A. Volund, J. A. Ehses, B. Seifert, T. Mandrup-Poulsen, and M. Y. Donath
Interleukin-1-Receptor Antagonist in Type 2 Diabetes Mellitus
N. Engl. J. Med., April 12, 2007; 356(15): 1517 - 1526.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
B. L. Wajchenberg
{beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment
Endocr. Rev., April 1, 2007; 28(2): 187 - 218.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes Spectr.Home page
B. P. Childs, N. C. Kesty, E. Klein, R. Rubin, and A. Wick
Considering Pramlintide Therapy for Postprandial Blood Glucose Control
Diabetes Spectr, April 1, 2007; 20(2): 108 - 114.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
O. Chan, M. Lawson, W. Zhu, J. L. Beverly, and R. S. Sherwin
ATP-Sensitive K+ Channels Regulate the Release of GABA in the Ventromedial Hypothalamus During Hypoglycemia
Diabetes, April 1, 2007; 56(4): 1120 - 1126.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. Rathmann, K. Kostev, B. Haastert, A. Parashar, A. Varma, R. Garg, G. Y. Gandhi, V. M. Montori, S. E. Kahn, G. Viberti, et al.
Glycemic Durability of Monotherapy for Diabetes
N. Engl. J. Med., March 29, 2007; 356(13): 1378 - 1380.
[Full Text] [PDF]

Home page
 J Public Health (Oxf)Home page
H. Patel, J. Srishanmuganathan, J. Car, and A. Majeed
Trends in the prescription and cost of diabetic medications and monitoring equipment in England 1991-2004
J. Public Health Med., March 1, 2007; 29(1): 48 - 52.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
L. B. Knudsen, D. Kiel, M. Teng, C. Behrens, D. Bhumralkar, J. T. Kodra, J. J. Holst, C. B. Jeppesen, M. D. Johnson, J. C. de Jong, et al.
From the Cover: Small-molecule agonists for the glucagon-like peptide 1 receptor
PNAS, January 16, 2007; 104(3): 937 - 942.
[Abstract] [Full Text] [PDF]

Home page
 Clin. DiabetesHome page
M. J. Fowler
Diabetes: Magnitude and Mechanisms
Clin. Diabetes, January 1, 2007; 25(1): 25 - 28.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R K. Campbell
Rationale for Dipeptidyl Peptidase 4 Inhibitors: A New Class of Oral Agents for the Treatment of Type 2 Diabetes Mellitus
Ann. Pharmacother., January 1, 2007; 41(1): 51 - 60.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
S. E. Kahn, S. M. Haffner, M. A. Heise, W. H. Herman, R. R. Holman, N. P. Jones, B. G. Kravitz, J. M. Lachin, M. C. O'Neill, B. Zinman, et al.
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
N. Engl. J. Med., December 7, 2006; 355(23): 2427 - 2443.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
H. Freeman and R.D. Cox
Type-2 diabetes: a cocktail of genetic discovery
Hum. Mol. Genet., October 15, 2006; 15(suppl_2): R202 - R209.
[Abstract] [Full Text] [PDF]

Home page
 Eur J EndocrinolHome page
W. S. Shim, S. K. Kim, H. J. Kim, E. S. Kang, C. W. Ahn, S. K. Lim, H. C. Lee, and B. S. Cha
Decrement of postprandial insulin secretion determines the progressive nature of type-2 diabetes.
Eur. J. Endocrinol., October 1, 2006; 155(4): 615 - 622.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
D. A Taylor-Fishwick, A. Bowman, N. Hamblet, P. Bernard, D. M Harlan, and A. I Vinik
Islet neogenesis associated protein transgenic mice are resistant to hyperglycemia induced by streptozotocin.
J. Endocrinol., September 1, 2006; 190(3): 729 - 737.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
M. S. Kirkman, R. R. Shankar, S. Shankar, C. Shen, E. Brizendine, A. Baron, and J. McGill
Treating postprandial hyperglycemia does not appear to delay progression of early type 2 diabetes: the early diabetes intervention program.
Diabetes Care, September 1, 2006; 29(9): 2095 - 2101.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Z. Khaldi, H. Elouil, Y. Guiot, J. C. Henquin, and J. C. Jonas
Antioxidants N-acetyl-L-cysteine and manganese(III)tetrakis (4-benzoic acid)porphyrin do not prevent beta-cell dysfunction in rat islets cultured in high glucose for 1 wk
Am J Physiol Endocrinol Metab, July 1, 2006; 291(1): E137 - E146.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
G. Sesti, E. Laratta, M. Cardellini, F. Andreozzi, S. Del Guerra, C. Irace, A. Gnasso, M. Grupillo, R. Lauro, M. L. Hribal, et al.
The E23K Variant of KCNJ11 Encoding the Pancreatic {beta}-Cell Adenosine 5'-Triphosphate-Sensitive Potassium Channel Subunit Kir6.2 Is Associated with an Increased Risk of Secondary Failure to Sulfonylurea in Patients with Type 2 Diabetes
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2334 - 2339.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
S. N. Davis and S. M. Renda
Treating to Target in Type 2 Diabetes: A Case Presentation.
The Diabetes Educator, June 1, 2006; 32(Supplement_4): 137S - 145S.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
S. N. Davis and S. M. Renda
Psychological Insulin Resistance: Overcoming Barriers to Starting Insulin Therapy.
The Diabetes Educator, June 1, 2006; 32(Supplement_4): 146S - 152S.
[Full Text] [PDF]

Home page
 DiabetesHome page
A. H. Xiang, C. Wang, R. K. Peters, E. Trigo, S. L. Kjos, and T. A. Buchanan
Coordinate Changes in Plasma Glucose and Pancreatic {beta}-Cell Function in Latino Women at High Risk for Type 2 Diabetes.
Diabetes, April 1, 2006; 55(4): 1074 - 1079.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Festa, K. Williams, R. D'Agostino Jr., L. E. Wagenknecht, and S. M. Haffner
The Natural Course of {beta}-Cell Function in Nondiabetic and Diabetic Individuals: The Insulin Resistance Atherosclerosis Study.
Diabetes, April 1, 2006; 55(4): 1114 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. O. Larsen, B. Rolin, J. Sturis, M. Wilken, R. D. Carr, N. Porksen, and C. F. Gotfredsen
Measurements of insulin responses as predictive markers of pancreatic beta-cell mass in normal and beta-cell-reduced lean and obese Gottingen minipigs in vivo
Am J Physiol Endocrinol Metab, April 1, 2006; 290(4): E670 - E677.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
D. A Taylor-Fishwick, W. Shi, G. L Pittenger, and A. I Vinik
PDX-1 can repress stimulus-induced activation of the INGAP promoter.
J. Endocrinol., March 1, 2006; 188(3): 611 - 621.
[Abstract] [Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
D. F. Kruger, C. L. Martin, and C. E. Sadler
New insights into glucose regulation.
The Diabetes Educator, March 1, 2006; 32(2): 221 - 228.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. A. Ritzel, A. E. Butler, R. A. Rizza, J. D. Veldhuis, and P. C. Butler
Relationship Between {beta}-Cell Mass and Fasting Blood Glucose Concentration in Humans.
Diabetes Care, March 1, 2006; 29(3): 717 - 718.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
L. Siminerio
Challenges and strategies for moving patients to injectable medications.
The Diabetes Educator, March 1, 2006; 32(2 Suppl): 82S - 90S.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
J. Meece
Dispelling Myths and Removing Barriers About Insulin in Type 2 Diabetes
The Diabetes Educator, January 1, 2006; 32(1): 9S - 18S.
[Full Text] [PDF]

Home page
 The Diabetes EducatorHome page
S. D. Wittlin
Treating the Spectrum of Type 2 Diabetes: Emphasis on Insulin Pump Therapy
The Diabetes Educator, January 1, 2006; 32(1): 39S - 46S.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
D. M. Kendall
Thiazolidinediones: The case for early use
Diabetes Care, January 1, 2006; 29(1): 154 - 157.
[Full Text] [PDF]

Home page
 CMAJHome page
R. L. Rothman and T. A. Elasy
Can diabetes management programs create sustained improvements in disease outcomes?
Can. Med. Assoc. J., December 6, 2005; 173(12): 1467 - 1468.
[Full Text] [PDF]

Home page
 NEJMHome page
J. A. Alarcon, J. M. Arribas, V. Ruiz, L. Czupryniak, M. Pawlowski, J. Loba, R. F. Bonvini, V. Verin, R. Waksman, R. M. Wolfram, et al.
Drug-eluting coronary stents.
N. Engl. J. Med., December 1, 2005; 353(22): 2404 - 2408.
[Full Text] [PDF]

Home page
 DiabetesHome page
M. Cnop, N. Welsh, J.-C. Jonas, A. Jorns, S. Lenzen, and D. L. Eizirik
Mechanisms of Pancreatic {beta}-Cell Death in Type 1 and Type 2 Diabetes: Many Differences, Few Similarities
Diabetes, December 1, 2005; 54(suppl_2): S97 - S107.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
M. Y. Donath, J. A. Ehses, K. Maedler, D. M. Schumann, H. Ellingsgaard, E. Eppler, and M. Reinecke
Mechanisms of {beta}-Cell Death in Type 2 Diabetes
Diabetes, December 1, 2005; 54(suppl_2): S108 - S113.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
N. Welsh, M. Cnop, I. Kharroubi, M. Bugliani, R. Lupi, P. Marchetti, and D. L. Eizirik
Is There a Role for Locally Produced Interleukin-1 in the Deleterious Effects of High Glucose or the Type 2 Diabetes Milieu to Human Pancreatic Islets?
Diabetes, November 1, 2005; 54(11): 3238 - 3244.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. T. Eurich, S. R. Majumdar, F. A. McAlister, R. T. Tsuyuki, and J. A. Johnson
Improved Clinical Outcomes Associated With Metformin in Patients With Diabetes and Heart Failure
Diabetes Care, October 1, 2005; 28(10): 2345 - 2351.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart J SupplHome page
C. J. Bailey
Overview of new and developing pharmacological treatments
Eur. Heart J. Suppl., June 1, 2005; 7(suppl_D): D23 - D26.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. N. Cook, C. J. Girman, P. P. Stein, C. M. Alexander, and R. R. Holman
Glycemic Control Continues to Deteriorate After Sulfonylureas Are Added to Metformin Among Patients With Type 2 Diabetes
Diabetes Care, May 1, 2005; 28(5): 995 - 1000.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
D. M. Kendall, M. C. Riddle, J. Rosenstock, D. Zhuang, D. D. Kim, M. S. Fineman, and A. D. Baron
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
Diabetes Care, May 1, 2005; 28(5): 1083 - 1091.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. A. DeFronzo, R. E. Ratner, J. Han, D. D. Kim, M. S. Fineman, and A. D. Baron
Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes
Diabetes Care, May 1, 2005; 28(5): 1092 - 1100.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
E. Blase, K. Taylor, H.-y. Gao, M. Wintle, and M. Fineman
Pharmacokinetics of an Oral Drug (Acetaminophen) Administered at Various Times in Relation to Subcutaneous Injection of Exenatide (Exendin-4) in Healthy Subjects
J. Clin. Pharmacol., May 1, 2005; 45(5): 570 - 577.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. S. Bell and G. L. Bakris
Carvedilol, Metoprolol, and Insulin Resistance--Reply
JAMA, March 9, 2005; 293(10): 1190 - 1190.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
M. H. Tan, A. Baksi, B. Krahulec, P. Kubalski, A. Stankiewicz, R. Urquhart, G. Edwards, D. Johns, and for the GLAL Study Group
Comparison of Pioglitazone and Gliclazide in Sustaining Glycemic Control Over 2 Years in Patients With Type 2 Diabetes
Diabetes Care, March 1, 2005; 28(3): 544 - 550.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
R. Padwal, S. R. Majumdar, J. A. Johnson, J. Varney, and F. A. McAlister
A Systematic Review of Drug Therapy to Delay or Prevent Type 2 Diabetes
Diabetes Care, March 1, 2005; 28(3): 736 - 744.
[Abstract] [Full Text] [PDF]

Home page
 J. Gerontol. A Biol. Sci. Med. Sci.Home page
M. P. Hermans, T. M. Pepersack, L. H. Godeaux, I. Beyer, and A. P. Turc
Prevalence and Determinants of Impaired Glucose Metabolism in Frail Elderly Patients: The Belgian Elderly Diabetes Survey (BEDS)
J. Gerontol. A Biol. Sci. Med. Sci., February 1, 2005; 60(2): 241 - 247.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
J. B. Dixon, W. J. Pories, P. E. O'Brien, P. R. Schauer, and P. Zimmet
Surgery as an Effective Early Intervention for Diabesity: Why the reluctance?
Diabetes Care, February 1, 2005; 28(2): 472 - 474.
[Full Text] [PDF]